Antidyskinetic effects of levetiracetam on levodopa-induced dyskinesias in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

被引：0
|
作者：
Loehle, M. [1 ]
Wolz, M. [1 ]
Strecker, K. [2 ]
Schneider, C. [1 ]
Schwanebeck, U. [3 ]
Reichmann, H. [1 ]
Graehlert, X. [3 ]
Schwarz, J. [2 ]
Storch, A. [1 ]
机构：
[1] Tech Univ Dresden, Dept Neurol, Dresden, Germany
[2] Univ Leipzig, Dept Neurol, Leipzig, Germany
[3] Tech Univ Dresden, Coordinat Ctr Clin Studies, Dresden, Germany
来源：
PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.103
引用
收藏
页码：S116 / S117
页数：2
相关论文
共 50 条
  • [1] Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial
    Martin Wolz
    Matthias Löhle
    Karl Strecker
    Uta Schwanebeck
    Christine Schneider
    Heinz Reichmann
    Xina Grählert
    Johannes Schwarz
    Alexander Storch
    [J]. Journal of Neural Transmission, 2010, 117 : 1279 - 1286
  • [2] Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial
    Wolz, Martin
    Lohle, Matthias
    Strecker, Karl
    Schwanebeck, Uta
    Schneider, Christine
    Reichmann, Heinz
    Graehlert, Xina
    Schwarz, Johannes
    Storch, Alexander
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (11) : 1279 - 1286
  • [3] The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study
    Snow, BJ
    Macdonald, L
    Mcauley, D
    Wallis, W
    [J]. CLINICAL NEUROPHARMACOLOGY, 2000, 23 (02) : 82 - 85
  • [4] Beneficial effect of levetiracetam on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled, crossover study (the VALID-PD study). Preliminary results
    Stathis, P.
    Konitsiotis, S.
    Tagaris, G.
    Hadjigeorgiou, G.
    Kiriakakis, V.
    [J]. MOVEMENT DISORDERS, 2008, 23 (01) : S202 - S202
  • [5] Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial
    Goetz, Christopher G.
    Damier, Philippe
    Hicking, Christine
    Laska, Eugene
    Mueller, Thomas
    Olanow, C. Warren
    Rascol, Olivier
    Russ, Hermann
    [J]. MOVEMENT DISORDERS, 2007, 22 (02) : 179 - 186
  • [6] A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Dyskinesia in Parkinson's Disease
    Wong, Kitty K.
    Alty, Jane E.
    Goy, Amanda G.
    Raghav, Sanjay
    Reutens, David C.
    Kempster, Peter A.
    [J]. MOVEMENT DISORDERS, 2011, 26 (08) : 1552 - 1555
  • [7] Levetiracetam for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
    Stathis, P.
    Konitsiotis, S.
    Tagaris, G.
    Peterson, D.
    [J]. MOVEMENT DISORDERS, 2011, 26 (02) : 264 - 270
  • [8] Botulinum toxin type A (BTX-A) in the management of levodopa-induced cervical dyskinesias in Parkinson's disease: A double-blind, randomized, placebo-controlled crossover study
    Vaughan, J. E.
    Duker, A. P.
    Jones, N.
    Gartner, M.
    Sahay, A.
    Revilla, F. J.
    Espay, A. J.
    [J]. MOVEMENT DISORDERS, 2009, 24 : S285 - S285
  • [9] Levetiracetam administration for the management of levodopa-induced dyskinesias in Parkinson's disease: An ongoing, multicenter, double-blind, placebo-controlled, parallel, crossover trial (the VALID-PD study) study design and baseline patient characteristics
    Stathis, P.
    Konitsiotis, S.
    Tagaris, G.
    Kyriakakis, V.
    Hadjigeorgiou, G.
    [J]. MOVEMENT DISORDERS, 2007, 22 : S237 - S238
  • [10] Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo controlled trial
    Goetz, C. G.
    Damier, P.
    Hicking, C.
    Lasko, E.
    Muller, T.
    Olanow, C. W.
    Rascol, O.
    Russ, H.
    [J]. MOVEMENT DISORDERS, 2006, 21 : S606 - S607
12345